Open access
Open access
Powered by Google Translator Translator

Cardiology (all articles)

RCT | Impact of empagliflozin on decongestion in acute heart failure.

23 Nov, 2022 | 14:04h | UTC

Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial – European Heart Journal

Commentary: Empagliflozin in Patients Hospitalized for Acute Heart Failure – EMPULSE – American College of Cardiology

 

Commentary on Twitter

 

Under a https://creativecommons.org/licenses/by-nc/4.0/ license

 

Cohort Study | Race-dependent association of HDL-C levels with incident coronary artery disease.

23 Nov, 2022 | 14:02h | UTC

Race-Dependent Association of High-Density Lipoprotein Cholesterol Levels With Incident Coronary Artery Disease – Journal of the American College of Cardiology

Editorial: HDL-C in Black Adults for ASCVD Risk Calculation: Benefit or Barrier to Achieving Health Equity? – Journal of the American College of Cardiology

News Release: Study challenges “good” cholesterol’s role in universally predicting heart disease risk – National Institutes of Health

Commentary: Study suggests that HDL or ‘good’ cholesterol is less beneficial than previously thought, especially for Black adults – CNN

 

RCT | Effects of a physical exercise intervention during vs. after chemotherapy to improve cardiorespiratory fitness.

23 Nov, 2022 | 14:01h | UTC

Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness: During or After Chemotherapy – JACC: CardioOncology

Editorial: Inclusion of Exercise in Cancer Treatment Planning: When Is the Right Time? – JACC: CardioOncology

Commentary: Exercise Intervention During Chemotherapy Beneficial – HealthDay

 

Cohort Study | Polygenic risk score improves the accuracy of a clinical risk score for coronary artery disease.

23 Nov, 2022 | 13:55h | UTC

Polygenic risk score improves the accuracy of a clinical risk score for coronary artery disease – BMC Medicine

Related:

AHA Scientific Statement | Polygenic risk scores for cardiovascular disease.

Incremental Value of Polygenic Risk Scores in Primary Prevention of Coronary Heart Disease: A Review – JAMA Internal Medicine

Cohort Study | Predictive utility of a validated polygenic risk score for long-term risk of coronary heart disease in young and middle-aged adults.

Cohort Study | Polygenic risk, midlife life’s simple 7, and lifetime risk of stroke.

Cohort Study: A polygenic risk score may improve risk stratification of coronary artery disease.

Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps.

Studies: Little Benefit from Polygenic Risk Score vs. Clinical Risk Score for Predicting Cardiovascular Risk

 

Commentary on Twitter

 

Cohort Study | Prognostic prediction of genotype vs. phenotype in genetic cardiomyopathies.

23 Nov, 2022 | 13:57h | UTC

Prognostic Prediction of Genotype vs Phenotype in Genetic Cardiomyopathies – Journal of the American College of Cardiology

 

Commentary on Twitter

 

Under a Creative Commons license

 

Right heart failure in the ED: approach to diagnosis and management.

23 Nov, 2022 | 13:54h | UTC

Right Heart Failure in the ED: Approach to Diagnosis and Management – emDocs

 

SR | Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.

22 Nov, 2022 | 13:39h | UTC

Blood pressure targets for the treatment of people with hypertension and cardiovascular disease – Cochrane Library 

Summary: Blood pressure targets in people with cardiovascular disease – Cochrane Library 

 

Commentary on Twitter 

https://twitter.com/CochraneUK/status/1594059435202289666

 

M-A | Bioresorbable scaffolds vs. drug-eluting stents for patients with myocardial infarction.

22 Nov, 2022 | 13:29h | UTC

Bioresorbable scaffolds vs. drug-eluting stents for patients with myocardial infarction: A systematic review and meta-analysis of randomized clinical trials – Frontiers in Cardiovascular Medicine 

Related: M-A | Bioresorbable vascular scaffolds are inferior compared to conventional drug-eluting stents across time. 

 

Cross-sectional study | Subretinal drusenoid deposits are strongly associated with coexistent high-risk vascular diseases.

22 Nov, 2022 | 13:27h | UTC

Subretinal drusenoid deposits are strongly associated with coexistent high-risk vascular diseases – BMJ Open Ophthalmology 

Commentaries:  

Specific AMD Phenotypes Strongly Associated with High-Risk Cardiovascular Disease – HCP Live 

Subretinal Drusenoid Deposits Linked to High-Risk Vascular Disease in AMD – HealthDay 

 

RCT | Subcutaneous vs. transvenous implantable cardioverter defibrillator implantations.

22 Nov, 2022 | 13:19h | UTC

Perioperative Safety and Early Patient and Device Outcomes Among Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Implantations: A Randomized, Multicenter Trial – Annals of Internal Medicine (link to abstract – $ for full-text) 

News Release: S-ICD Associated with 92 Percent Reduction in Lead-Related Complications Typical in Patients with ICDs – American College of Physicians 

Commentaries: 

Subcutaneous ICD Reduces Lead-Related Complications – HealthDay 

Subcutaneous implantable cardioverter defibrillators reduce the risk of perioperative complications – Physician’s Weekly 

Related: 

Device-related complications in subcutaneous versus transvenous ICD: a secondary analysis of the PRAETORIAN trial – European Heart Journal 

Subcutaneous or Transvenous Defibrillator Therapy – New England Journal of Medicine 

 

Commentary on Twitter 

 

 

2ry analysis of a RCT | Device-related complications in subcutaneous versus transvenous ICD.

22 Nov, 2022 | 13:16h | UTC

Device-related complications in subcutaneous versus transvenous ICD: a secondary analysis of the PRAETORIAN trial – European Heart Journal 

Original Study: Subcutaneous or Transvenous Defibrillator Therapy – New England Journal of Medicine 

Related: Perioperative Safety and Early Patient and Device Outcomes Among Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Implantations: A Randomized, Multicenter Trial – Annals of Internal Medicine (link to abstract – $ for full-text) 

 

Pooled analysis of 4 studies | Drug-coated balloons vs. bare metal stents in patients with femoropopliteal arterial disease.

22 Nov, 2022 | 13:02h | UTC

Comparison of Drug-coated Balloons versus Bare Metal Stents in Patients with Femoropopliteal Arterial Disease – Journal of the American College of Cardiology 

Commentary: New studies support use of drug-coated balloons over bare metal stents in treating femoropopliteal lesions – University Hospitals Cleveland Medical Center 

 

M-A | Lower vs. higher exposure to vasopressor therapy in vasodilatory hypotension.

21 Nov, 2022 | 14:16h | UTC

Lower Versus Higher Exposure to Vasopressor Therapy in Vasodilatory Hypotension: A Systematic Review With Meta-Analysis – Critical Care Medicine 

 

RCT | Influenza vaccine to reduce adverse vascular events in patients with heart failure.

18 Nov, 2022 | 13:26h | UTC

Influenza vaccine to reduce adverse vascular events in patients with heart failure: a multinational randomised, double-blind, placebo-controlled trial – The Lancet Global Health

Commentary: 

Flu vaccines cut pneumonia, cardiovascular issues in heart failure patients – CIDRAP

Flu Shot Could Be Lifesaver for Folks With Heart Failure – HealthDay

 

M-A | Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction.

18 Nov, 2022 | 13:14h | UTC

Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials – Cardiovascular Diabetology

 

RCT | Clopidogrel is better than Aspirin for chronic maintenance monotherapy after percutaneous coronary intervention.

17 Nov, 2022 | 12:30h | UTC

Aspirin vs. Clopidogrel for Chronic Maintenance Monotherapy after Percutaneous Coronary Intervention: the HOST-EXAM Extended Study – Circulation

Related: 

Meta-analysis of randomized trials: Clopidogrel is better than aspirin for the secondary prevention of cardiovascular events.

#ACC21 – RCT: Clopidogrel better than aspirin for chronic maintenance monotherapy after percutaneous coronary intervention.

 

Commentary on Twitter

https://twitter.com/CircAHA/status/1589647384073703426 

 

Sudden cardiac death in the young: a consensus statement on recommended practices for cardiac examination by the pathologist.

17 Nov, 2022 | 12:27h | UTC

Sudden Cardiac Death in the Young: A Consensus Statement on Recommended Practices for Cardiac Examination by the Pathologist from the Society for Cardiovascular Pathology – Cardiovascular Pathology

 

Mild-to-moderate kidney dysfunction and cardiovascular disease: observational and mendelian randomization analyses.

17 Nov, 2022 | 12:18h | UTC

Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses – Circulation

 

Commentary on Twitter

https://twitter.com/CircAHA/status/1587897418989080577

 

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials.

17 Nov, 2022 | 12:17h | UTC

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials – European Heart Journal

Commentary: Inclisiran and Cardiovascular Events – American College of Cardiology

 

Commentary on Twitter

https://twitter.com/ESC_Journals/status/1592113799481692162

 

Review | POCUS for aortic dissection in the clinical presentation of ischemic stroke.

17 Nov, 2022 | 12:08h | UTC

POCUS for aortic dissection in the clinical presentation of ischemic stroke – emDocs

 

RCT | Comparative effects of low-dose rosuvastatin vs. dietary supplements on lipids and inflammatory biomarkers.

16 Nov, 2022 | 13:41h | UTC

Comparative Effects of Low-Dose Rosuvastatin, Placebo and Dietary Supplements on Lipids and Inflammatory Biomarkers – Journal of the American College of Cardiology

News Release: 6 common “heart-health” supplements ineffective at lowering cholesterol compared to statins – American Heart Association

Commentaries: 

Study – For Lowering Cholesterol, Statins Work, Supplements Don’t – Science-Based Medicine

Statins vs. supplements: New study finds one is ‘vastly superior’ to cut cholesterol – NPR

 

Cohort Study | Childhood adversity and cardiovascular disease in early adulthood.

16 Nov, 2022 | 13:29h | UTC

Childhood adversity and cardiovascular disease in early adulthood: a Danish cohort study – European Heart Journal (free for a limited period)

Commentary: Study explores the links between childhood adversity and cardiovascular disease in early adulthood – European Society of Cardiology/News Medical

 

Commentary from the author on Twitter

https://twitter.com/HulvejRod/status/1592520830155886593

 

AHA Scientific Statement | An overview of telehealth in the management of cardiovascular disease.

15 Nov, 2022 | 13:01h | UTC

An Overview of Telehealth in the Management of Cardiovascular Disease: A Scientific Statement From the American Heart Association – Circulation

News Release: Telehealth is a valuable option in cardiovascular care, though challenges remain – American Heart Association

 

RCT | Bivalirudin is superior to heparin in patients with ST-segment elevation myocardial infarction undergoing primary PCI.

15 Nov, 2022 | 13:00h | UTC

Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial – The Lancet

Commentaries:

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI – TCTMD

Bivalirudin found to be safer and more effective than heparin for treating heart attack patients undergoing percutaneous coronary intervention – Mount Sinai School of Medicine

BivaliRudin with prolonged full-dose Infusion during primary PCI versus Heparin Trial – BRIGHT-4 – American College of Cardiology

 

M-A | SGLT2 inhibitors reduce the risk of kidney disease progression and AKI, irrespective of diabetes status.

11 Nov, 2022 | 14:04h | UTC

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials – The Lancet

Commentaries:

Meta-analysis backs SGLT2 inhibitors for kidney disease – medwire News

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD – TCTMD

Related: RCT | In patients with CKD (eGFR 20-45 mL/min per 1.73 m2), Empagliflozin reduced the risk of progression of kidney disease.

 

Commentary on Twitter

Under a Creative Commons Attribution (CC BY 4.0) License

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.